Sumitomo Chemical Reports Consolidated Financial Results For the Three Months Ended June 30, 2006

Sumitomo Chemical Company, Limited today announced that its consolidated net sales for the three months ended June 30, 2006 totaled ¥412.3 billion (\$3,578 million), a 22.7% increase over the same period last year. Net income decreased 6.0% to ¥ 20.4 billion (\$177 million).

Sales in the Basic Chemicals Segment increased by 21.8% over the same period the previous year, to ¥69.9 billion. Aluminum sales increased considerably as market conditions improved. Sales of methyl methacrylate (MMA) were boosted by the recent capacity expansion at our production facilities in Singapore. Sales in the Petrochemical & Plastics Segment increased by 9.3% over the same period last year to ¥125.2 billion. Sales of synthetic resins remained firm both in Japan and overseas. Styrene monomer and other petrochemicals showed increased sales, reflecting rising prices for naphtha and other feedstocks. Sales in the Fine Chemicals Segment rose by 17.9% compared with the corresponding period last year to ¥22.1 billion. Robust sales of adhesives raw materials and pharmaceutical chemicals helped enhance the segment's total sales. Sales in the IT-related Chemicals Segment increased by 34.5% over the same period the previous year to ¥63.8 billion. Polarizing film, a material used in liquid crystal displays (LCDs), saw sales growth from production capacity expansions, mainly at our plant in Korea. Sales in the Agricultural Chemicals Segment increased by 11.8% over the same period last year to ¥44.7 billion. The segment's improved sales are attributable to healthy sales of herbicides in the North American market, and sales promotion activities helped increase sales of feed additives. Shipments of Olyset® Nets rose as a result of production capacity expansion. Sales in the Pharmaceuticals Segment increased by 27.1% over the same period the previous year to ¥58.8 billion. Dainippon Sumitomo Pharma, formed by the merger of Sumitomo Pharmaceuticals and Dainippon Pharmaceutical in October 2005, showed increased sales owing to the strong performance of their four major products, Amlodin (a therapeutic agent for hypertension and angina), Gasmotin (gastroprokinetic), Meropen (carbapenem antibiotic) and Prorenal (vasodilator) as well as the effect of the merger. Increased shipments of these products contributed to the improved overall performance of the new company, in spite of National Health Insurance price reductions implemented in April of this year. Sales in the Others Segment rose by 137.3% compared with the corresponding period last year to ¥27.8 billion.

<u>Total operating income</u> increased by 14.4% over the same period the previous year to ¥34.0 billion. Operating income declined by 12.6% to 2.7 billion in Basic Chemicals and by 37.4% to 3.6 billion in Petrochemicals & Plastics, because of the impact of a rise in raw material costs and other factors. Operating income in the IT-related Chemicals Segment was ¥3.7 billion, remaining at the same level as the previous year because of a decrease in selling prices. On the other hand, operating income in Agricultural Chemicals improved by 97.9% to 4.6 billion, and for Pharmaceuticals by 27.3% to 15.3 billion thanks to an increase in shipments.

<u>Net income</u> decreased by 6.0% to ¥20.4 billion as a result of a decrease in equity in the earnings of affiliates and an increase in special losses due to restructuring charges.

(Note) *U.S. dollar amounts are translated from yen, for convenience only, at the rate of ¥115.24= \$1 prevailing on June 30, 2006.

(Cautionary Statement)

Statements made in this release with respect to the Company's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace; Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

Summary of Consolidated Results

(1) Results of operations:

	3 Months ended June 30 , 2006			3 Months ended	
				June 30 , 2005	
	(¥ Million)	(US\$ 1,000) [*]	(¥ Million)
Net Sales	¥	412,301	\$	3,577,759	¥ 336,087
Operating Income		33,982		294,880	29,706
Income Before Income Taxes					
and Minority Interests		40,159		348,481	43,325
Net Income		20,355		176,631	21,664
Net in some non 1 000 shows	(X	Yen)	(US\$) [*]	(Yen) ¥ 13.108
Net income per 1,000 shares	¥	12,322	\$	107	¥ 13,108

(2) Financial Position:

	As of June 30, 2006			As of March 31, 2006	
(¥ Million)	(US\$ 1,000) [*]	(¥ Million)
¥	2,164,966	\$	18,787	¥	2,178,377
	940,658		8,163		719,760
(¥	Yen) 433 285	(\$	US\$) [*] 3 760	(¥	Yen) 435,510
	(¥	(¥ Million) ¥ 2,164,966 940,658	(¥ Million) (¥ 2,164,966 \$ 940,658 (Yen) ($\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

(3) Results of Operations by Business Segment:

	3 Months ended June 30 , 2006			3 Months ended June 30 , 2005		
	()	¥ Million)	(US\$ 1,000) [*]	(¥ Million)
Net Sales						
Basic Chemicals	¥	69,902	\$	606,578	¥	57,372
Petrochemicals & Plastics		125,155		1,086,038		114,511
Fine Chemicals		22,086		191,652		18,739
IT-related Chemicals		63,844		554,009		47,461
Agricultural Chemicals		44,721		388,068		40,016
Pharmaceuticals		58,786		510,118		46,269
Others		27,807		241,296		11,719
	¥	412,301	\$	3,577,759	¥	336,087
Operating Income						
Basic Chemicals	¥	2,718	\$	23,586	¥	3,111
Petrochemicals & Plastics		3,629		31,491		5,797
Fine Chemicals		3,214		27,890		2,475
IT-related Chemicals		3,734		32,402		3,808
Agricultural Chemicals		4,616		40,056		2,333
Pharmaceuticals		15,283		132,619		12,009
Others		728		6,317		206
Elimination		60		521		(33)
	¥	33,982	\$	294,880	¥	29,706

(Note)

*U.S. dollar amounts are translated from yen, for convenience only, at the rate of ¥115.24= \$1 prevailing on June 30, 2006.